Category: Latest News

  • Ares Capital Q2 earnings fall short of estimates, shares dip slightly

    Ares Capital Q2 earnings fall short of estimates, shares dip slightly

    Ares Capital Corporation (NASDAQ:ARCC) reported second-quarter 2025 earnings on Tuesday that missed analyst expectations, causing a slight decline in its shares. Shares slipped 0.22% in pre-market trading following the announcement. The business development company posted core earnings per share of $0.50, just below the consensus estimate of $0.51. Total investment income reached $745 million, marginally…

  • JetBlue shares climb over 2% after beating Q2 expectations

    JetBlue shares climb over 2% after beating Q2 expectations

    JetBlue Airways Corp (NASDAQ:JBLU) posted stronger-than-expected second-quarter results on Tuesday, delivering a positive operating margin despite ongoing industry challenges. The airline reported a narrower loss than anticipated, reflecting progress in its multi-year transformation plan. Shares of JetBlue rose 2.29% in pre-market trading following the earnings release. The company reported a second-quarter loss of $0.21 per…

  • Incyte misses Q2 earnings estimates but raises Jakafi full-year guidance

    Incyte misses Q2 earnings estimates but raises Jakafi full-year guidance

    Incyte Corporation (NASDAQ:INCY) reported second-quarter results on Tuesday that fell well short of analyst earnings expectations, though the company boosted its full-year revenue outlook for its leading drug Jakafi. Following the announcement, shares in the biotech firm edged up 0.3%. Incyte posted breakeven earnings per share for the quarter, missing consensus estimates of $1.40 by…

  • Asbury Automotive Group beats Q2 earnings expectations, shares rise

    Asbury Automotive Group beats Q2 earnings expectations, shares rise

    Asbury Automotive Group (NYSE:ABG) reported second-quarter earnings on Tuesday that surpassed analyst forecasts, driven by strong profitability despite slightly lower-than-expected revenue. Shares rose 1.75% in pre-market trading following the announcement. The automotive retailer posted adjusted earnings of $7.43 per diluted share, well above the $6.83 consensus estimate. Revenue came in at $4.4 billion, a bit…

  • Union Pacific to acquire Norfolk Southern in $320-per-share deal, creating America’s first transcontinental railroad

    Union Pacific to acquire Norfolk Southern in $320-per-share deal, creating America’s first transcontinental railroad

    Union Pacific Corporation (NYSE:UNP) announced Tuesday it will acquire rival Norfolk Southern Corporation (NYSE:NSC) in a cash-and-stock transaction valued at $320 per share, aiming to form the first transcontinental railroad in the U.S. The offer represents a 25% premium over Norfolk Southern’s 30-day volume-weighted average price as of July 16. Following the announcement, Union Pacific…

  • Exelixis shares tumble over 12% after revenue miss and zanzalintinib trial halt

    Exelixis shares tumble over 12% after revenue miss and zanzalintinib trial halt

    Exelixis Inc. (NASDAQ:EXEL) shares dropped more than 12% in pre-market trading Tuesday following its Q2 earnings report and the announcement to discontinue development of its experimental cancer drug zanzalintinib in a head-and-neck cancer trial. For the quarter ending June 30, 2025, Exelixis reported total revenues of $568.3 million, including $520.2 million in net product revenues…

  • Fulcrum Therapeutics shares slide 17% after sickle cell trial results

    Fulcrum Therapeutics shares slide 17% after sickle cell trial results

    Fulcrum Therapeutics Inc. (NASDAQ:FULC) saw its stock drop 17% on Tuesday, wiping out earlier gains following the release of data from the 12 mg dose cohort in its Phase 1b PIONEER trial of pociredir for sickle cell disease. The Cambridge, Massachusetts-based biopharma reported an absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline after…

  • Alkermes shares climb 5% following Q2 earnings and revenue beat

    Alkermes shares climb 5% following Q2 earnings and revenue beat

    Alkermes plc (NASDAQ:ALKS) reported stronger-than-expected second-quarter results on Tuesday, driven by solid performance across its proprietary product lineup. Shares rose 5.16% in pre-market trading after the announcement. The biopharmaceutical firm posted adjusted earnings of $0.52 per share, well above the $0.36 consensus estimate. Revenue totaled $390.7 million, beating expectations of $347.16 million despite a 2.1%…

  • Apellis shares jump 12% following FDA approval of first-ever C3G treatment

    Apellis shares jump 12% following FDA approval of first-ever C3G treatment

    Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) saw its stock soar 12% after the U.S. Food and Drug Administration (FDA) granted approval for EMPAVELI® (pegcetacoplan), the first approved therapy for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and older. This approval represents a major advance for individuals affected by these rare…

  • Corning shares climb over 2% following strong AI-driven earnings beat

    Corning shares climb over 2% following strong AI-driven earnings beat

    Corning Incorporated (NYSE:GLW) saw its shares rise 2.45% in pre-market trading Tuesday after reporting better-than-expected second-quarter results fueled by high demand for products linked to artificial intelligence. The materials science firm posted core earnings per share of $0.60 for the quarter, surpassing the analyst forecast of $0.57. Revenue reached $4.05 billion, beating estimates of $3.86…